聚乙二醇化干扰素与普通干扰素治疗慢性乙型肝炎成本-效果分析

目的对聚乙二醇化干扰素（PEG．IFN）与普通干扰素（IFN）治疗慢性乙型肝炎进行经济学评价。方法对本院门诊诊治的210例慢性乙型肝炎患者的48周诊疗经过和疗效进行统计,包括ALT复常率、HBVDNA转阴率、HBeAg转阴率及其血清学转换率、HBsAg转阴率及其血清学转换率。结果PEG-IFN与IFN均对慢性乙型肝炎有效,ALT复常率分别为70％、53．3％,HBVDNA转阴率分别为73．33％、56．67％,HBeAg转阴率分别为42．22％、37．5％,HBsAg转阴率分别为7．78％、1．67％。PEG-IFN组和IFN组的有效率分别为66．67％,50．83％。获得相同效果时,IFN组的成本明显低于PEG-IFN组。结论治疗慢性乙型肝炎48周,PEG—IFN组的有效率较1FN组高,而IFN组成本一效果比较低。     

干扰素联合利巴韦林治疗丙型肝炎22例临床观察

目的观察干扰素（α-2b1NF）联合利巴韦林治疗丙型肝炎的疗效。方法 治疗组应用α-2b1NF、利巴韦林口服．对照组单用α-2b1NF、均治疗24周。观察两组治疗结束及停药26周时ALT复常率、HCV—RNA阴转率。结果 治疗组ALT复常率为77．3％和72．7％．HCV-RNA阴转率为68．2％和59．0％；对照组ALT复常率为66．7％和52．4％．HCV-RNA阴转率为47．6％和28．6％．两组结果差异有统计学意义。结论 α-2b1NF联合利巴韦林治疗丙型肝炎．可提高远期疗效。     

重组人干扰素a-2b联合利巴韦林治疗丙型肝炎的临床研究

目的：探讨重组人干扰素a-2b联合利巴韦林治疗丙型肝炎的临床疗效。方法：将2011～2013年我院收治的136例丙型肝炎患者按不同治疗方法分为试验组（72例,基础治疗＋重组人干扰素a-2b＋利巴韦林）和对照组（64例,基础治疗＋普通干扰素-2b＋利巴韦林）,对两组治疗后患者ALT复常率及HCV-RNA阴转率情况进行综合比较。结果：试验组治疗12周、24周后的ALT复常率明显高于对照组（P＜0.05）,两组治疗12周后的HCV-RNA阴转率比较无明显差异（P＞0.05）;但试验组在治疗24周、48周后的HCV-RNA阴转率明显高于对照组（P＜0.05）。结论：重组人干扰素a-2b联合利巴韦林治疗丙型肝炎效果显著,能明显改善患者ALT及HCV-RNA水平,值得临床推广应用。     

聚乙二醇化干扰素α-2a联合利巴韦林治疗慢性丙型肝炎疗效观察

目的：探讨聚乙二醇化干扰素α-2a（PEG-IFN α-2a,派罗欣）联合利巴韦林（RBV）治疗慢性丙型肝炎疗效。方法：30例慢性丙型肝炎患者根据体重不同每周皮下注射1次PEG-IFN α-2a 180μg或135μg,同时联合利巴韦林800～1000 mg/d,分别于治疗前及治疗后4、12、24、48周时检测ALT（谷丙转氨酶）及HCV RNA（丙型肝炎病毒核糖核酸）定量。结果：30例患者根据基因分型均按预计完成疗程（28例治疗48周,2例治疗24周）,HCV RNA阴转率在治疗4周时达90%,在12、24和48周时均达100%。ALT复常率在治疗结束时,24周达95%,48周达94.4%。结论：PEG-IFN α-2a联合利巴韦林在慢性丙型肝炎治疗中显示了良好的病毒学及生化学应答反应,且提高了患者治疗依从性,能取得比较好的治疗效果。     

干扰素联合利巴韦林治疗慢性丙型肝炎的临床观察

目的:观察普通干扰素联合利巴韦林治疗慢性丙型肝炎的疗效。方法:治疗组32例慢性丙型肝炎患者采用普通干扰素联合利巴韦林治疗,对照组30例慢性丙型肝炎患者采用普通干扰素治疗,于治疗前、治疗24周结束,及随访24周分别检测肝功ALT、HCVRNA。结果:治疗组24周后肝功复常率为76.6%、HCVRNA阴转率为80.0%,治疗结束后随访24周ALT复常率为66.7%、HCVRNA阴转率为63.3%。与对照组疗效比较差异有显著性。结论:普通干扰素联合利巴韦林治疗慢性丙型肝炎效果显著,价格适中,值得进一步推广和应用。     

大剂量胸腺肽合并干扰素治疗慢性丙型肝炎疗效观察

目的　探讨大剂量胸腺肽合并干扰素治疗慢性丙型肝炎的疗效和安全性。方法　治疗组以胸腺肽 16 0mg加10 %葡萄糖 2 5 0ml静脉滴注 ,每周 3次。α干扰素 3MIU肌注 ,每周 3次。对照组 ,单用α干扰素 3MIU肌注 ,每周 3次 ,疗程均为 6个月。结果　大剂量胸腺肽合并干扰素治疗组HCVRNA阴转率 6 6 6 7% ,ALT复常率 76 19% ,对照组HCVRNA阴转率33 33% ,ALT复常率 76 19% ,对照组HCVRNA阴转率 33 33% ,ALT复常率 5 2 38% ,两组经统计学处理有显著差异 ( P <0 0 5 )。结论　大剂量胸腺肽合并干扰素治疗慢性丙型肝炎疗效好 ,较安全     

干扰素联合利巴韦林治疗丙型肝炎临床疗效分析

目的研究干扰素联合利巴韦林治疗丙型肝炎的疗效。方法回顾本院60例慢性丙型肝炎患者,随即分为治疗组与对照组,分别使用干扰素及干扰素联合利巴韦林进行治疗,观察疗效。结果治疗组ALT复常率及HCV-RNA阴转率均高于对照组,不良反应发生率高于对照组。结论干扰素联合利巴韦林治疗丙型肝炎,只要注意选择病例及用量,是一种有效的方法。     

低剂量干扰素与利巴韦林治疗丙肝代偿期肝硬化的效果探究

目的分析低剂量干扰素与利巴韦林治疗丙肝代偿期肝硬化的效果。方法抽取入住我院的38例丙肝代偿期肝硬化患者(2010年11月至2014年9月)作为本次实验的研究对象,对其实施随机分组。对照组19例患者采取利巴韦林治疗,实验组19例患者采取低剂量干扰素与利巴韦林治疗,比较两组丙肝代偿期肝硬化患者的临床疗效(持续病毒学应答率、HCV-RNA阴转率及ALT复常率)及不良反应发生率。结果对照组患者的不良反应发生率(15.79%)和实验组患者(21.05%)无明显区别,但实验组和对照组丙肝代偿期肝硬化患者的持续病毒学应答率、HCV-RNA阴转率及ALT复常率存在明显差异,P<0.05。结论对丙肝代偿期肝硬化患者采取低剂量干扰素与利巴韦林进行治疗,效果明显,可有效抑制病毒复制,降低患者的病死率。     

拉米夫定联合干扰素治疗慢性乙型肝炎

目的观察拉米夫定(LAM)联合干扰素(IFN)治疗慢性乙型肝炎(CHB)的疗效。方法147例CHB患者分为三组,A组为联合治疗组,B组为IFN组,C组为LAM组,定期(4、8、12、24、36、48周)观察患者病毒学和血清学变化情况。结果(1)A、B、C三组48周的HBeAb的阳转率分别为31.88%、20.00%、11.54%,A组明显高于C组(P<0.01)。(2)A组HBVYMDD变异发生率低于C组(P<0.05)。(3)A、B、C三组48周的丙氨酸氨基转移酶(ALT)的复常率分别为89.47%(34/38)、76.00%(19/25)和76.92%(60/78)。48周HBVDNA阴转率分别为89.47%(34/38)、80.00%(20/25)和88.46%(69/78)。结论联合应用拉米夫定和干扰素治疗慢性乙型肝炎可增加e系统的血清转换;但与单独用药比较在ALT复常率和HBVDNA清除率方面无明显差异。     

大剂量胸腺肽合并干扰素治疗慢性丙型肝炎疗效观察

目的 探讨大剂量胸腺肽合并干扰素治疗慢性丙型肝炎的疗效和安全性。方法 治疗组以胸腺肽160mg加10％葡萄糖250ml静脉滴注，每周3次。α干扰素3MIU肌注，每周3次。对照组，单用α干扰素3MIU肌注，每周3次，疗程均为6个月。结果 大剂量胸腺肽合并干扰素治疗组HCVRNA阴转率66．67％，ALT复常率76．19％，对照组HCV RNA阴转率33．33％，ALT复常率76．19％，对照组HCV RNA阴转率33．33％，ALT复常率52．38％，两组经统计学处理有显著差异（P＜0．05）。结论 大剂量胸腺肽合并干扰素治疗慢性丙型肝炎疗效好，较安全。     

Effect of interferon alpha,interferon beta,and interferon gamma on the in vitro growth of human renal adenocarcinoma cells

Interferon-, interferon-, and interferon- differ in their antiproliferative effects for several cell lines. Interferons were thus assessed for their activity in inhibiting proliferation of three renal cell carcinoma cell lines. The malignant epithelial phenotype of each of these cell lines was confirmed by electron microscopy, histology, karyotype and tumorigenicity. When compared on an anti-viral unit basis, naturally produced interferon- was more effective than natural interferon- for all cell lines and clones. Proliferation of each of the cell lines was inhibited by interferon-. In all cases, removal of interferons from culture media resulted in resumption of the rate of cell growth after a variable delay of 6–10 days. If the antiproliferative effects of interferons predominate in mediating tumor regression, clinical response may depend upon the type of interferon to which the tumor is exposed.     

The interferon system: inhibitors of interferon action]

The review of the literature data and the authors' data on interferon action inhibitors being one of the components of interferon system is presented. The methods of the production of various types of interferon action inhibitors, their characteristics and the main differences between them are described. The possible mechanisms of inhibitors' actions are considered. It was shown that the study of interferon action inhibitors is important in both the theoretical and practical aspects.     

干扰素基因多态性与干扰素治疗慢性乙肝早期应答的关系

干扰素(IFN)是慢性乙型肝炎(CHB)的主要治疗药物之一。但应用IFN治疗的人群应答效果往往差异很大,其原因除了乙肝病毒(HBV)本身生物学特征及宿主对HBV的免疫状态等因素外,宿主IFN遗传通道上众多基因的单核苷酸多态性(SNP)也是影响IFN应答的重要因素。IFN-γ基因874     

重组干扰素α-1b治疗慢性丙型肝炎的疗效研究

目的探讨重组干扰素α-1b(赛若金)治疗慢性丙型肝炎的疗效及不良反应.方法选择慢性丙型肝炎患者65例,随机分成治疗组35例,给予赛若金治疗,第1～4周30μg·     

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon

BACKGROUND: Up to 80% of hepatitis C patients are refractory to treatment with interferon-alpha. These patients are not likely to benefit from higher dosages or longer duration of interferon alone. The addition of ribavirin has been shown to improve the response rate in patients resistant to a previous course of interferon-alpha alone. AIM: To evaluate whether a sustained hepatitis C virus (HCV) RNA response could be obtained with combination therapy of interferon-alpha and ribavirin in patients who did not respond to or relapsed after a standard interferon-alpha treatment. METHODS: A total of 73 patients, 59 non-responders and 14 relapsers after interferon-alpha alone, were treated with a combination of ribavirin (1000-1200 mg/day) and interferon-alpha (3 MU three times a week) for 24 weeks. Alanine aminotransferase levels and HCV RNA were checked for 24 weeks after completion of therapy. RESULTS: At the end of the combination therapy, 36 patients (49%) showed alanine aminotransferase normalization and in 20 patients (27%), HCV RNA was undetectable in serum. At the end of the 24 weeks follow-up period, only 12 patients (16%) had a sustained response with serum negativity of HCV RNA. This response was significantly higher in relapsers than in non-responders: five (36%) vs. seven (12%) patients (P=0.03), respectively. Adverse effects were restricted to flu-like symptoms and moderate haemolytic anaemia. CONCLUSIONS: Combination of interferon-alpha and ribavirin is quite limited, both in scope and efficacy, in HCV patients who had a non-response to monotherapy with interferon. Better results may be expected in relapsers, but larger studies are necessary.     

Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C

INTRODUCTION: Combination therapy with pegylated interferon alpha (Peg-interferon) and ribavirin is currently the cornerstone of antiviral therapy for chronic hepatitis C. Monotherapy with Peg-interferon still is important for the treatment of chronic hepatitis B. With the advent of new therapies, protease inhibitors for chronic hepatitis C and nucleotide inhibitors for chronic hepatitis B, there remains a need for interferon-based therapies. The side effects of Peg-interferon are a main disadvantage and represent a stumbling block for many patients to enter and continue therapy. AREAS COVERED: In this review, the authors will discuss controlled-release interferon alpha 2b (CR2b) (Locteron?, Biolex Therapeutics, Pittsboro, NC, USA), a new slow-release interferon alpha 2b preparation for the treatment of chronic viral hepatitis. Other alternative interferons will also be discussed. EXPERT OPINION: CR2b is a slow-release microsphere preparation for the administration of plant-derived recombinant human interferon alpha 2b. Compared with Peg-interferon, treatment with CR2b shows less flu-like reactions and less depression, and is at least as effective as conventional Peg-interferon-based therapy in patients with chronic hepatitis C. CR2b has the added advantage of biweekly instead of once weekly administration. CR2b appears to cause more neutropenia than Peg-interferon alpha 2b. This may be due to higher trough serum levels of CR2b at the end of a dosing interval. The bone marrow effects of CR2b closely resemble those published for the registered Peg-interferon alpha 2a. CR2b appears to have at least comparable efficacy with fewer side effects than current registered Peg-interferons.